AMENDED AND RESTATED DEVELOPMENT AND COMMERCIALIZATION LICENSE AGREEMENTDevelopment and Commercialization License Agreement • July 31st, 2020 • Opko Health, Inc. • Pharmaceutical preparations • New York
This Amended and Restated Development and Commercialization License Agreement (the “Agreement”) is entered into as of May 12, 2020 (the “Amendment Execution Date”) and is made effective as of January 1, 2020 (the “Amendment Effective Date”), by and between Pfizer Inc., a Delaware corporation with offices located at 235 East 42nd Street, New York, New York 10017 (“Pfizer”) and OPKO Ireland Ltd., an entity organized and existing under the laws of Ireland (“OPKO”). Pfizer and OPKO are referred to herein individually as a “Party” and collectively as the “Parties.”
DEVELOPMENT AND COMMERCIALIZATION LICENSE AGREEMENTDevelopment and Commercialization License Agreement • April 16th, 2019
This Development and Commercialization License Agreement (the “Agreement”) is entered into as of December 13, 2014 (the “Execution Date”), by and between Pfizer Inc., a Delaware corporation with offices located at 235 East 42nd Street, New York, New York 10017 (“Pfizer”) and OPKO Ireland Ltd., an entity organized and existing under the laws of Ireland (“OPKO”). Pfizer and OPKO are referred to herein individually as a “Party” and collectively as the “Parties.”
DEVELOPMENT AND COMMERCIALIZATION LICENSE AGREEMENTDevelopment and Commercialization License Agreement • February 27th, 2015 • Opko Health, Inc. • Pharmaceutical preparations • New York
This Development and Commercialization License Agreement (the “Agreement”) is entered into as of December 13, 2014 (the “Execution Date”), by and between Pfizer Inc., a Delaware corporation with offices located at 235 East 42nd Street, New York, New York 10017 (“Pfizer”) and OPKO Ireland Ltd., an entity organized and existing under the laws of Ireland (“OPKO”). Pfizer and OPKO are referred to herein individually as a “Party” and collectively as the “Parties.”
DEVELOPMENT AND COMMERCIALIZATION LICENSE AGREEMENTDevelopment and Commercialization License Agreement • August 7th, 2009 • Ardea Biosciences, Inc./De • Pharmaceutical preparations • New York
This Development and Commercialization License Agreement (the “Agreement”), is entered into as of April 27, 2009 (the “Signing Date”) by and between Ardea Biosciences, Inc., a Delaware corporation, having an address of 4939 Directors Place, San Diego, California 92121, USA (“Ardea”), and Bayer Schering Pharma AG, a corporation organized under the laws of Germany, having an address of Müllerstrasse 178, 13353 Berlin, Germany (“Bayer”).
